🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

OraSure Technologies, Inc. OSUR R2K

Healthcare · Medical Instruments & Supplies · United States
https://www.orasure.com
Company Profile ↓
$4.25
+38.44% 1Y
Mkt Cap$292.61M
P/E-4.05
P/B0.95
52W High$4.50
52W Low$2.11
Book Value$4.51
EPS (TTM)$-1.05

Company Overview

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.

Recent Developments

  • Dec 2025 Revenue of $115.02M (-38.1% YoY); net profit $-68.73M.
  • Trailing 12 Months Year-on-year growth — revenue -6.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 2.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:2.54%
1 Year:-6.70%

Stock Price Performance

1 Year:+38.44%
6 Months:+57.99%
3 Months:+32.40%
1 Month:+1.67%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 90% of range
$2.11 $4.50
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)53.02 · Neutral
Price Performance
1M+1.67%
3M+32.40%
6M+57.99%
1Y+38.44%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-4.05
Industry PE
25.88
Forward P/E
-8.45
PEG Ratio
6.19
Book Value
$4.51
Price to Book
0.95
P/S
2.60
EV/EBITDA
-2.10
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
2.54%
Profit 5Y
-
Revenue (YoY)
-6.70%
Earnings (YoY)
-

Profitability & Returns

ROCE
-19.81%
ROE
-21.16%
ROA
-10.65%
Profit Margin
-66.42%
Op Margin
-78.45%
Gross Margin
42.27%
EPS (Latest Qtr)
$-0.32
EPS (TTM)
$-1.05

Balance Sheet & Liquidity

Debt/Equity
4.04
Quick Ratio
4.61
Current Ratio
5.46
Debt
$12.66M
Total Assets
$379.17M
Current Assets
$261.91M
Working Capital
$222.11M

Ownership

Promoter Holding
6.38%
Chg in Prom Hold
0.01%
FII / Inst Holding
89.12%
Chg in FII Hold
0.30%

Financial Snapshot

Enterprise Value
$292.61M
Total Revenue (TTM)
$113.02M
EBITDA
$-61.54M
Free Cash Flow
$-8.89M
Operating Cash Flow
$-43.19M
Shares Outstanding
68.85M
Gross Margin
42.27%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 OSUR OraSure Technologies, Inc. R2K 4.25 -4.05 $292.61M 0.00% -19.81% -21.16% 2.54% -
2 LLY Eli Lilly and Company SPX 1,156.63 41.13 $1.03T 0.60% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 247.02 28.66 $594.63B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.11 119.08 $431.29B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 418.52 31.54 $380.08B 2.18% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 123.61 34.82 $305.29B 2.82% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 168.37 26.10 $261.12B 1.87% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 535.29 29.40 $198.93B 0.35% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 358.32 24.92 $193.39B 2.80% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -------32.55M40.18M42.31M-41.99M43.62M45.88M-30.12M38.83M35.99M-31.60M29.26M48.01M58.58M57.61M53.92M67.71M80.23M116.46M154.96M85.44M89.19M54.13M54.34M39.91M-29.93M31.24M27.09M26.76M27.93M
Cost of Revenue -----------------------------------17.63M18.08M15.31M15.79M16.12M
Gross Profit 20.70M20.67M-20.31M21.09M22.68M-20.31M25.48M24.64M-24.47M25.89M28.55M-18.08M25.02M21.65M-16.13M17.26M30.29M38.33M30.67M21.47M24.30M27.80M46.51M65.81M26.37M44.34M24.07M24.69M17.07M-12.30M13.16M11.77M10.97M11.80M
Operating Expenses -----------------------------------30.56M30.45M27.49M27.82M34.98M
Operating Income 2.72M1.54M4.09M2.70M4.35M6.14M7.07M15.87M6.89M7.32M10.16M-498.00K5.56M10.86M12.51M-3.81M5.29M13.05M4.08M-8.05M-9.40M4.38M10.42M1.80M-13.01M-16.17M-21.47M866.00K24.32M-6.43M10.89M-7.09M-2.74M-6.00M--18.27M-17.29M-15.71M-16.85M-23.18M
EBITDA ------------------------------------15.49M-14.88M-13.33M-14.45M-20.92M
Interest Expense ----------------------------------------
Pretax Income ------------------------------------15.97M-16.89M-13.29M-18.43M-21.72M
Tax Provision ------------------------------------456.00K2.00M47.00K210.00K-432.00K
Net Income 1.97M1.47M4.62M2.45M3.84M6.24M7.20M12.44M5.43M5.76M7.32M-2.12M4.12M8.10M10.30M-3.26M4.40M13.08M2.44M-7.33M-10.49M1.04M3.77M-1.36M-15.02M27.22M-18.59M5.59M27.22M-4.80M11.16M-3.58M-615.00K-4.51M--16.04M-19.69M-13.71M-19.29M-22.38M
Diluted EPS 0.030.030.080.040.070.110.130.210.090.090.12-0.030.070.130.16-0.050.070.210.04-0.12-0.160.010.05-0.02-0.21-0.28-0.260.080.37-0.070.15-0.05-0.01-0.06--0.21-0.26-0.19-0.27-0.32
R&D Expense 3.00M2.52M-2.37M2.98M3.20M-2.97M3.34M3.23M-4.08M4.26M3.85M-4.37M4.54M4.62M-5.64M6.92M8.01M8.99M7.68M8.60M8.63M9.46M10.09M10.56M7.66M8.52M7.74M6.60M5.62M-9.60M11.40M10.11M-13.65M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 77.03M75.02M81.88M87.82M98.94M106.46M119.72M128.20M167.06M181.74M154.60M171.72M233.67M387.48M405.47M185.83M115.02M
Gross Profit 47.13M47.36M51.72M55.57M58.59M66.62M80.29M88.03M98.96M113.61M94.58M101.87M117.60M148.44M171.65M79.39M48.20M
Operating Income -8.79M-3.35M-9.40M-16.27M-12.16M-4.80M8.06M20.27M40.24M28.43M18.61M-5.18M-10.16M-22.16M32.68M-28.25M-71.97M
Net Income -7.81M-3.50M-8.84M-15.12M-11.19M-4.61M8.17M19.72M30.95M20.40M16.66M-14.92M-23.00M-17.13M53.66M-19.50M-68.73M
Diluted EPS --0.08-0.19-0.29-0.20-0.080.140.350.510.330.270.22-0.32-0.240.72-0.26-0.94
R&D Expense 13.37M13.19M18.41M12.45M10.93M12.06M11.65M9.75M13.37M16.25M19.63M31.03M34.17M36.24M33.73M26.05M42.53M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Jan 2013Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --122.52M127.86M191.44M-184.25M189.63M189.32M207.94M296.20M315.57M349.30M454.47M-444.18M482.85M479.66M403.17M
Current Assets ---------------325.19M386.46M333.22M261.91M
Cash & Equivalents 39.57M74.93M73.84M23.88M87.89M87.89M93.19M92.87M94.09M107.96M71.03M88.44M75.72M160.80M-83.98M290.41M267.76M199.28M
Inventory ---------------95.70M47.61M34.20M31.06M
Receivables ---------------70.80M40.17M23.82M22.20M
Total Liabilities -----------32.19M42.15M55.90M-79.75M52.17M69.32M62.34M
Current Liabilities --19.68M21.98M16.63M-18.98M26.46M25.23M17.34M32.24M27.98M32.71M46.49M-69.06M39.54M33.48M39.80M
Long Term Debt -------------------
Total Debt ---------------12.55M13.50M14.60M13.20M
Total Equity 108.33M103.81M102.84M100.25M170.31M170.31M161.15M158.70M159.44M185.85M258.08M283.38M307.14M398.57M-364.43M430.67M410.34M340.83M
Shares Outstanding ---------------72.73M73.53M74.60M70.39M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -292.76K3.89M-2.99M-5.37M8.38M--24.60M28.16M39.09M9.80M5.81M-35.38M-47.20M141.58M27.37M-49.02M
Investing Cash Flow 36.90M-3.77M-50.34M-2.02M-2.46M---8.06M-96.35M-17.43M-19.80M-14.03M-5.50M21.09M66.15M-39.03M-6.81M
Financing Cash Flow -1.23M-1.21M3.37M71.43M-420.00K---1.16M30.43M-1.89M-4.68M92.48M-2.82M-3.83M-3.02M-4.18M-16.94M
Capital Expenditure -1.20M-2.11M-2.50M-2.02M-2.46M-3.00M-3.74M-4.35M-4.34M-6.34M-9.31M-26.67M-21.89M-6.77M-5.80M-3.80M-4.20M
Free Cash Flow -1.49M1.78M-5.50M-7.39M5.92M--20.25M23.82M32.75M490.00K-20.87M-57.27M-53.98M135.78M23.58M-53.22M
Share Buybacks 700.20K709.00K909.00K1.56M829.00K639.00K6.09M3.44M1.24M3.59M3.71M2.09M2.11M2.25M0015.04M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 61.2%63.1%63.2%63.3%59.2%62.6%67.1%68.7%59.2%62.5%61.2%59.3%50.3%38.3%42.3%42.7%41.9%
Operating Margin % -11.4%-4.5%-11.5%-18.5%-12.3%-4.5%6.7%15.8%24.1%15.6%12.0%-3.0%-4.3%-5.7%8.1%-15.2%-62.6%
Net Margin % -10.1%-4.7%-10.8%-17.2%-11.3%-4.3%6.8%15.4%18.5%11.2%10.8%-8.7%-9.8%-4.4%13.2%-10.5%-59.8%
ROE % -7.5%-3.4%-8.8%-8.9%-6.9%-2.9%5.1%10.6%12.0%7.2%5.4%-3.7%--4.7%12.5%-4.8%-20.2%
ROCE % --3.3%-8.9%-9.3%-7.4%-2.9%4.9%10.6%15.2%9.9%5.9%-1.3%--5.9%7.4%-6.3%-19.8%

Shareholding Pattern

Insiders
6.38%
Institutions
89.12%
Public Float
95.19%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 9.46% 6.52M $27.86M
2 Private Management Group, Inc. 7.88% 5.42M $23.18M
3 Neuberger Berman Group, LLC 6.34% 4.36M $18.65M
4 Altai Capital Management, L.p. 5.25% 3.61M $15.45M
5 Vanguard Capital Management LLC 4.40% 3.03M $12.96M
6 Dimensional Fund Advisors LP 4.10% 2.82M $12.06M
7 Systematic Financial Management, L.P. 3.60% 2.48M $10.60M
8 Renaissance Technologies, LLC 3.03% 2.08M $8.91M
9 Acadian Asset Management. LLC 2.94% 2.02M $8.64M
10 Cannell Capital LLC 2.91% 2.00M $8.56M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for OSUR

Google News hu, 16 Apr 2026

Why OraSure Technologies (OSUR) Is Back in the Spotlight as Sale Pressure Builds - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNelRtekF3N2Jad09GVnMtMnh4V0E3bUVpdXoyZ1RXMEQ1dVNaX1VZLTZPZ2k3NHpyckNFVHhzM3ljZXpkWkJxSTFGU05aUnl6VjVYSDFOaVJYbGVGNTcybmlzdXR4UXYtY0VfdkVEdVB4TXJFUWt4RmlvLXRab3hidlRGVXhYcExCNG9wZU…

Google News ue, 30 Jun 2026

OraSure Technologies (OSUR) director takes 3,666-share stock grant in lieu of cash - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPaE1Cd2VEQ2lSaVV1eTFENVVKUkxWVlE1SUo0VDBTcXRpeTdoV0RLYjlZZnVrRjBPSXdqVFJGYjhLZ0dIc3lvSVBaV2czS21wLXF5RFBtYlBTSWV5dnlkbjdTN2NSN05DNmdiY200ZjNRU1EzUExIWnliZENYd0FUel9YLXpDdkV4N3BhSk…

Google News ue, 17 Mar 2026

Altai Capital presses OraSure to sell and give it board seats, letter says - Reuters

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxNOWk4TEd4ZTRKcHhVZUE3NkFiNEFiUnNlek5kOWJ2V0tnbUpGc1pJcnhnNG4zQXFSR25Oam5FNnBFMUtVbUhsRE1aNFBBS1lLOG1uSFVYLS1nNGZ2YzN2Ym1HMWp4a1JIN1Y0T3NSTFNZZlIwbzJtZERxSjMtcGFLcFJVTVBZTG41R3M4Qm…

Google News hu, 11 Jun 2026

OraSure stock jumps on FDA clearance for at-home STI kit - Investing.com

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQbUtTbnctR0lEX3ZkMVV6TlNiWkdsWE9acFhLUUk1R085WC1Lam1obXpCVlBmSFJNcFBvSzd4UjBnTjcxd1h4SDRGX1RnQXVoRjQ2NzBKZmJrVVJpUUR5alFtb2tGTkJpN1hUUENOV0FJd1ZIZE5tcFVtcThpZUVXalBnTEpoMW1qRldLa1…

Google News hu, 11 Jun 2026

FDA clears at-home urine kit that lets labs test for 4 STIs by mail - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPX2JWdG1mOTNMVm1tUEZkUTNpWjdSNHlsTW13WGg1OHc3eTNLRVpUczJHLThWblhmV2VDQUpUX19SdTJraW4xYnZrVS1udDc1dU1fTWdLLWRzNlBPX3lvWG84R3p1d0RreDJoby1OdkR6Rm51YUQ5NEZDeGhOR1hpaG8zZkQtMnEzNzM2ZW…

Google News Fri, 08 Aug 2025

OraSure Technologies, Inc. (NASDAQ:OSUR) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxQdmxxWjJmV1QyVWluRktIX2szR2tLZkNXbDJQNmxnMGNiT2VVOEdyalA5T1lDbXNyMGl0NW90RGxkOGMtWlJiMTdpNTJiWElkTmNsU1BTeFlRTDBuN21kWE5BQXE5bjg3dWpnTU9PeGd5eUtiYjNJcVZnRURSUzkxWC14TGNlMm5hbElJTE…

OSUR — Frequently Asked Questions

What is the current share price of OraSure Technologies, Inc. (OSUR)?

As of 2026-07-15 16:51 PDT, OraSure Technologies, Inc. (OSUR) trades at $4.25 on NasdaqGS. Its 52-week range is $2.11 to $4.50.

What is the market capitalisation of OSUR?

OraSure Technologies, Inc. (OSUR) has a market capitalisation of $292.61M on NasdaqGS.

What is the P/E ratio of OSUR?

OSUR trades at a trailing price-to-earnings (P/E) ratio of -4.05. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 0.95.

What is the return on equity (ROE) of OSUR?

OSUR has a return on equity (ROE) of -21.16%. Its return on capital employed (ROCE) is -19.81%.

Is OSUR a good stock to buy?

This page provides a data-driven analysis of OraSure Technologies, Inc. (OSUR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space